Credit Suisse reiterates ViaCell at outperform

ViaCell Inc. was rated at outperform with a $10 target price by Credit Suisse analyst Mark Augustine. The company presented preclinical data demonstrating that stem cell transplantation can improve heart function following an acute myocardial infarction. All efficacy measurements showed impressive dose-dependent improvements in cardiac function after four weeks. Shares of the Cambridge, Mass., biotechnology company were down 20 cents, or 3.51%, at $5.50 on volume of 269,797 shares versus the three-month running average of 213,048 shares. (Nasdaq: VIAC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.